Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Chronic thromboembolic pulmonary hypertension: animal models

Olaf Mercier, Elie Fadel
European Respiratory Journal 2013 41: 1200-1206; DOI: 10.1183/09031936.00101612
Olaf Mercier
Laboratory of Surgical Research and INSERM U999, Hôpital Marie-Lannelongue and Paris-Sud University, Le Plessis Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: o.mercier@ccml.fr
Elie Fadel
Laboratory of Surgical Research and INSERM U999, Hôpital Marie-Lannelongue and Paris-Sud University, Le Plessis Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening disease due to pulmonary artery obstruction by persistent organised clots related to one or more episodes of acute pulmonary embolism. To date, the pathogenesis of CTEPH remains unexplained. Pulmonary endarterectomy removes obstruction from pulmonary vessels and can cure patients. However, some unreachable distal pulmonary obstruction and/or associated distal pulmonary vasculopathy could induce persistent pulmonary hypertension, the main postoperative complication.

The pathophysiology of CTEPH is not fully understood and improving knowledge of this disease could improve our future surgical and medical management. Many attempts, conducted over several decades, have failed to reproduce this chronic disease in animals. However, several animal models have provided insights into the pathophysiology and pathogenesis of CTEPH. Here, we review all the animal models that have improved the comprehension of CTEPH and hold promise for further investigations. This short review analyses strengths and weaknesses of all animal models available to study the pathophysiology of CTEPH.

  • Chronic thromboembolic pulmonary hypertension
  • pulmonary circulation
  • remodelling
  • right ventricular function

Regarding the Dana Point 2009 clinical classification [1], chronic thromboembolic pulmonary hypertension (CTEPH) is a type-4 subtype of pulmonary hypertension (PH), in which pulmonary endarterectomy (PEA) [2] is effective in preventing death by right ventricle (RV) failure. CTEPH is due to obstruction of pulmonary arteries by persistent organised clots formed during one or more episodes of acute pulmonary embolism. The reason for clot persistence is unknown and the pathogenesis of CTEPH remains unexplained. To date, the lack of risk factors predicting the evolution from acute pulmonary embolism to CTEPH does not allow the development of preventive care and/or screening programmes.

The increase in pulmonary vascular resistance is believed to result from a combination of proximal pulmonary artery obstruction and distal pulmonary vasculopathy [3, 4], which have to be quantified before PEA to estimate risks and predict surgical success. However, the mechanisms underlying lesion development in the obstructed and unobstructed peripheral vascular beds remain unknown. Hence, medical management of inoperable CTEPH or operable CTEPH with an important distal vasculopathy remains troublesome because of a lack of efficient therapy.

To elucidate the pathophysiology of CTEPH, considerable effort has been expended in attempting to develop reliable animal models. Acute pulmonary embolism is easily produced in several animal species. In contrast, the induction of a disease replicating all the components of human CTEPH has proved challenging. These components consist of clot persistence and organisation, pulmonary hypertension, chronic pulmonary-artery obstruction by unresolved intraluminal material, the development of a systemic blood supply to ischemic lung regions, pulmonary vasculopathy in unobstructed territories, and RV remodelling. Here, we review all the animal models described in the international literature that have been used to study the pathogenesis and pathophysiology of CTEPH (table 1).

View this table:
  • View inline
  • View popup
Table 1– Insights into thrombus resolution and organisation learned from stagnant flow induced inferior vena cava thrombus animal models

ANIMAL MODELS OF PERSISTENT INTRAVASCULAR THROMBOSIS

The mechanisms by which the pulmonary emboli or thrombi fail to undergo lysis and instead organise into occluding fibrotic material remain unknown. Hypotheses include predisposing pulmonary endothelial cell abnormalities [42] and impairments in the vascular repair process [43]. A role for in situ thrombosis related to endothelial cell dysfunction may explain why up to 63% of patients with CTEPH have no documented history of acute pulmonary embolism [3]. This hypothesis has not been studied in animals, as no endothelial cell abnormalities have been identified to date in humans with CTEPH. In contrast, the process of thrombus organisation has been studied in reliable animal models of low flow-induced inferior vena cava thrombosis (table 2). Most of these animal models were developed in rodents, with the goal of investigating venous thrombus resolution [5–22]. Thrombosis can be induced by venous stasis alone or combined with induced blood hypercoagulability or mechanical endothelial damage. Kang et al. [13] studied a piglet model of jugular vein thrombosis after stenosis and mechanical endothelial damage [15]. Inferior vena cava occlusion has been also studied in monkeys [15]. However, mice and rats remain the most widely used animals due their cost-effectiveness and efficiency [7]. Low-flow rodent models are characterised by a laminar thrombus that resolves within 3–4 weeks via a process of recanalisation that requires inflammatory cell recruitment and angiogenic signals [5–11, 17–22].

View this table:
  • View inline
  • View popup
Table 2– Current animal models used to study pathogenesis and pathobiology of chronic thromboembolic pulmonary hypertension

In studies of clinical risk factors, CTEPH was associated neither with the classical plasma-factor abnormalities associated with venous thromboembolism nor with impairments in fibrinolysis. However, having a ventriculo-atrial shunt or history of pacemaker infection increased the risk of CTEPH [44, 45]. This finding prompted studies in animal models. Thus, Bonderman et al.[23] used a mouse model of low-flow venous thrombosis induced by inferior vena cava stenosis and endothelial damage to study the role for staphylococcal infection in delaying thrombus resolution and promoting the expression of profibrotic molecules.

DUAL VASCULAR COMPARTMENT THEORY

Moser et al. [4] were the first to describe two compartments in the pulmonary vascular bed of CTEPH patients: an obstructed compartment subjected to chronic ischemia and an unobstructed compartment subjected to increased flow and shear stress (fig. 1). Thus, in addition to the obstruction of large pulmonary arteries, patients with CTEPH have vascular lesions in distal unobstructed territories. These distal lesions are similar to those found in patients with other forms of PH.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Anteroposterior pulmonary angiogram showing the two vascular territories in a patient with chronic thromboembolic pulmonary hypertension. The obstructed territory is subjected to chronic ischaemia and the unobstructed territory to an increase in blood flow.

Many observations are consistent with a role for both territories in increasing pulmonary-vascular resistance. First, for the same degree of pulmonary artery obstruction as measured by lung scanning, CTEPH is associated with higher pulmonary resistance values compared to acute pulmonary embolism [46]. Secondly, the onset of CTEPH disease is characterised by an asymptomatic honeymoon period during which pulmonary vascular resistance increases gradually without evidence of recurrent embolism. These two vascular compartments have been reproduced in animals separately and, more recently, simultaneously in a piglet model.

MODELS REPLICATING PULMONARY ARTERY OBSTRUCTION

The first attempt to replicate chronic pulmonary artery obstruction in an animal model was conducted in piglets by Fadel et al. [24] who used proximal embolisation of coils and tissue adhesive into the left pulmonary artery. Chronic obstruction (for 5 weeks) of the left pulmonary artery resulted in chronic lung ischemia without PH. The result was an increase in the systemic blood supply to the lung via bronchial, mediastinal, and intercostal arteries, as well as distal post-obstructive pulmonary vasculopathy. These lesions were similar to those seen after chronic pulmonary artery ligation [25].

The left pulmonary artery was chosen for ligation, because it could be easily re-implanted into the main pulmonary artery to replicate reperfusion injuries after PEA. The systemic vascular response to chronic-pulmonary vascular obstruction differs across species, with proliferation of bronchial arteries into the intraparenchymal airways in large animals (dogs and piglets) and rats or of intercostal arteries into the pleural space in mice [26]. Although CTEPH studies have been conducted chiefly in piglets, a few studies of bronchial circulation have been performed in a rat model of pulmonary artery ligation [27]. Occlusion of one of the main pulmonary arteries stimulates angiogenesis in the bronchial vessels of the ipsilateral lung [28]. Bronchial arteries begin to enlarge as soon as 2–3 days after pulmonary artery ligation and supply the pulmonary circulation via precapillary anastomoses. These anastomoses may maintain airway epithelium oxygenation, thus explaining the lesser degree of reperfusion injury after chronic lung ischemia than after acute lung ischemia [29].

In addition to bronchial circulation hypertrophy, post-obstructive vasculopathy is characterised by pulmonary artery abnormalities including increased media thickness [30], impaired vasoreactivity [31], impaired endothelial nitric-oxide-synthase function [30], and increased reactivity to endothelin (ET)-1 [32] leading to increased resistance after reperfusion [33].

Lung reperfusion after chronic ischemia was followed by gradual reversal of the post-obstructive vasculopathy [25, 34], after an early phase of ischemia-reperfusion injury with endothelial cell damage [35].

Closure of the aorto-pulmonary shunt replicates the hemodynamic conditions in unobstructed territories after PEA. Shunt closure induced normalisation of ET-1 and ETA expression, followed by media hypertrophy reversal in the distal pulmonary arteries. These findings were consistent with the gradual improvement in pulmonary vascular resistance observed 3–6 months after PEA.

MODELS REPLICATING LESIONS OF UNOBSTRUCTED PULMONARY ARTERIES

During the early phase of CTEPH, the unobstructed territories are subjected to a chronic blood flow increase due to cardiac output redistribution. Therefore, systemic-to-pulmonary shunts have been used in animals to replicate the lesions seen in unobstructed territories in patients with CETPH [36]. In an animal model initially developed by Rendas et al. [37] to replicate congenital heart disease, an aorto-pulmonary shunt is induced by implanting a short prosthesis between the ascending aorta and main pulmonary artery. This model has been used to induce high-flow pulmonary vascular lesions similar to those seen in unobstructed territories in CTEPH (fig. 2). As with the left pulmonary artery ligation models, the aorto-pulmonary shunt was achieved through a median sternotomy to avoid pleural opening and a subsequent inflammatory response. High-flow pulmonary vasculopathy induced by 5 weeks of aorto-pulmonary shunting was characterised by increased media thickness of the distal pulmonary arteries (fig. 3) related to smooth muscle cell proliferation (as shown by proliferating cell nuclear antigen labelling) and by elevated levels of ET-1 and its receptor endothelin receptor A (ETA) in lung tissue. ET-1 is a potent vasoconstrictor and mitotic peptide for vascular smooth muscle cells. ET-1 overexpression has been found in other animal models of high pulmonary flow [38–40]. ET-1 overproduction is probably a response to stimuli such as shear stress resulting from arterial pressure elevation [47].

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

Aortography showing in a sham-group piglet. a) The aortic arch with the two supra-aortic arteries. b) Visualisation of the pulmonary vascular bed (white arrow) at the same time as the aortic arch after creation of an aorto-pulmonary shunt. c) No opacification of the pulmonary vascular bed after shunt closure.

Figure 3–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3–

Box plot of media thickness as a percentage of small pulmonary arteries (<150 μm) calculated in: the sham (35.9±0.8%), shunt-open (55.6±1.2%), 1-week shunt-closed (48.7±1%), and 5-weeks shunt-closed (40.9±1%) groups [36]. Media thickness percentage was calculated as follows: external diameter minus internal diameter and divided by the external diameter. Aorto-pulmonary shunting was created by a graft interposition between the ascending aorta and the pulmonary trunk in piglets. Closure of the shunt was obtained by dividing the graft.

ANIMAL MODEL REPLICATING ALL FEATURES OF CTEPH

Although the animal models described earlier provided useful information on impaired thrombus resolution and on the pathophysiology of lesions in obstructed and unobstructed territories, they failed to replicate important features of human CTEPH including pulmonary hypertension, interactions between the two pulmonary vascular compartments and, above all, RV remodelling and dysfunction.

Since the 1990s, several attempts to develop animal models of CTEPH [48–52] failed because of clot lysis by the very efficient endogenous fibrinolytic system [53] and of the remarkable adaptive capabilities of the pulmonary circulation. Thus, 3 h after acute pulmonary embolism in dogs [49], only 30% of the initial injected thrombus volume remained inside the pulmonary artery. Adding tranexamic acid [49] or plasminogen activator inhibitor-1 [50] to delay thrombus resorption between injections failed to solve this problem. The second difficulty was the large pulmonary circulation reserve, which required obstruction of more than half the pulmonary vasculature to achieve an increase in pulmonary vascular resistance. The adaptive capabilities of the pulmonary vasculature explain why repeated injections of small, inert, non-absorbable materials failed to replicate CTEPH. Thus, in a dog model of chronic pulmonary-artery injections of ceramic beads, 3 mm in diameter, pulmonary pressures and resistances returned to normal within 1 week after each injection [51]. With 100–300 μm microspheres, 60 days of repeated embolisation were required to increase the pulmonary-artery pressure [52]. After 60 days, signs of PH started to develop, but there was no bronchial artery hypertrophy, post-obstructive or high-flow vasculopathy, or proximal vascular obstruction [52]. A third challenge lies in replicating RV remodelling. Extensive acute obstruction of the pulmonary arterial tree is usually lethal by heart failure in the absence of previous RV training and hypertrophy. To tolerate a persistent increase in pulmonary arterial pressure, the RV must undergo remodelling, which consists in gradual ventricular wall hypertrophy followed by right-heart-chamber enlargement with a paradoxical septal motion. In the event of persistent pulmonary hypertension, RV failure develops.

We recently developed a CTEPH piglet model [41], consisting of a primary left pulmonary artery ligation via a sternotomy that was followed by weekly transcatheter embolisations, under fluoroscopic control, of the tissue adhesive enbucrilate (Histoacryl) into the right lower lobe for 5 weeks. Pulmonary artery ligation overwhelmed the pulmonary circulation reserve and led to PH within a few weeks, with progressive obstruction of the remaining lung vasculature. The progressive nature of the obstruction achieved via weekly embolisation allowed the RV to adapt to the pressure increase, thus preventing death by acute RV failure. The tissue adhesive enbucrilate solidifies immediately after contact with blood and adheres to the arterial wall. The result was proximal obstruction by unresolved material in the right lower-lobe artery. Thus, the right upper-lobe arteries remained patent and exhibited lesions replicating those seen in unobstructed territories in CTEPH. After 5 weeks, this piglet model replicated all the features of human CTEPH: increased pulmonary vascular resistance, increased mean pulmonary artery pressure, increased media thickness of distal pulmonary arteries in both obstructed and unobstructed territories, increased systemic blood supply through the bronchial arteries in the obstructed territories, RV hypertrophy, RV enlargement, and paradoxical septal motion (fig. 4). Interestingly, although the embolisations were stopped after 5 weeks, the increase in pulmonary vascular resistance persisted for up to 1 month later after the last embolisation (unpublished data). Overexpression of ET-1 and its receptors ETA and ETB was documented in the remodelled distal arteries of the unobstructed territories, in keeping with previous findings in piglets with high-flow vasculopathy [36, 38]. In addition, ETA overexpression in the obstructed territories was consistent with the results of previous studies of post-obstructive vasculopathy [33]. Further experiments are needed to monitor pulmonary resistance at a distance from the last pulmonary embolisation, to investigate RV remodelling and failure, and to assess interactions between the obstructed and unobstructed territories. However, one should bear in mind that this model does not replicate the impaired thrombus resolution seen in human CTEPH.

Figure 4–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4–

Chronic thromboembolic pulmonary hypertension piglet model consisting of left pulmonary artery ligation and repeated embolisation in the right lower lobe: bronchial artery hypertrophy in the ischaemic lung territory (b), apparently normal right upper lobe (a), unresolved intravascular material made of tissue adhesive and fibrin moulding the arterial tree, and right ventricle remodelling.

CONCLUSIONS

Animal models developed over several decades have provided valuable information on the pathophysiology of CTEPH. Thrombus resolution and obstructed and unobstructed territories have been studied separately in several animal models. Recently, a model replicating all the major aspects of human CTEPH was developed. This model should prove useful for investigating RV dysfunction and distal lung vessel abnormalities. However, additional models are still needed to elucidate the pathobiology of thrombus persistence.

Footnotes

  • Previous articles in this Series. No. 1: Delcroix M, Vonk-Noordegraaf A, Fadel E, et al. Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J 2013; 41: 224–232. No. 2: Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013; 41: 462–468. No. 3: Jenkins DP, Madani M, Mayer E, et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2013; 41: 735–742. No. 4: Pepke-Zaba J, Jansa P, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J 2013; 41: 985–990.

  • Statement of Interest

    None declared.

  • Received July 2, 2012.
  • Accepted December 8, 2012.
  • ©ERS 2013

REFERENCES

  1. ↵
    1. Simonneau G,
    2. Robbins IM,
    3. Beghetti M,
    4. et al
    . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43–S54.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Dartevelle P,
    2. Fadel E,
    3. Mussot S,
    4. et al
    . Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 637–648.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hoeper MM,
    2. Mayer E,
    3. Simonneau G,
    4. et al
    . Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–2020.
    OpenUrlFREE Full Text
  4. ↵
    1. Moser KM,
    2. Bloor CM
    . Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685–692.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Modarai B,
    2. Humphries J,
    3. Burnand KG,
    4. et al
    . Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution. Arterioscler Thromb Vasc Biol 2008; 28: 1753–1759.
    OpenUrlAbstract/FREE Full Text
    1. Waltham M,
    2. Burnand K,
    3. Fenske C,
    4. et al
    . Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. J Vasc Surg 2005; 42: 1183–1189.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Modarai B,
    2. Burnand KG,
    3. Humphries J,
    4. et al
    . The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost 2005; 93: 801–809.
    OpenUrlPubMed
    1. Waltham M,
    2. Burnand KG,
    3. Collins M,
    4. et al
    . Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation. Thromb Haemost 2003; 89: 169–176.
    OpenUrlPubMedWeb of Science
    1. McGuinness CL,
    2. Humphries J,
    3. Waltham M,
    4. et al
    . Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost 2001; 85: 1018–1024.
    OpenUrlPubMedWeb of Science
    1. Waltham M,
    2. Burnand KG,
    3. Collins M,
    4. et al
    . Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 2000; 32: 988–996.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Humphries J,
    2. McGuinness CL,
    3. Smith A,
    4. et al
    . Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg 1999; 30: 894–899.
    OpenUrlCrossRefPubMed
    1. Singh I,
    2. Burnand KG,
    3. Collins M,
    4. et al
    . Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107: 869–875.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kang C,
    2. Bonneau M,
    3. Brouland JP,
    4. et al
    . In vivo pig models of venous thrombosis mimicking human disease. Thromb Haemost 2003; 89: 256–263.
    OpenUrlPubMed
    1. Londy FJ,
    2. Kadell AM,
    3. Wrobleski SK,
    4. et al
    . Detection of perivenous inflammation in a rat model of venous thrombosis using MRV. J Invest Surg 1999; 12: 151–156.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Fowlkes JB,
    2. Strieter RM,
    3. Downing LJ,
    4. et al
    . Ultrasound echogenicity in experimental venous thrombosis. Ultrasound Med Biol 1998; 24: 1175–1182.
    OpenUrlCrossRefPubMedWeb of Science
    1. Millet J,
    2. Vaillot M,
    3. Theveniaux J,
    4. et al
    . Experimental venous thrombosis induced by homologous serum in the rat. Thromb Res 1996; 81: 497–502.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Wakefield TW,
    2. Linn MJ,
    3. Henke PK,
    4. et al
    . Neovascularization during venous thrombosis organization: a preliminary study. J Vasc Surg 1999; 30: 885–892.
    OpenUrlCrossRefPubMedWeb of Science
    1. Henke PK,
    2. Wakefield TW,
    3. Kadell AM,
    4. et al
    . Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001; 99: 84–91.
    OpenUrlCrossRefPubMedWeb of Science
    1. Varma MR,
    2. Varga AJ,
    3. Knipp BS,
    4. et al
    . Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg 2003; 38: 1090–1098.
    OpenUrlCrossRefPubMed
    1. Henke PK,
    2. Varga A,
    3. De S,
    4. et al
    . Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol 2004; 24: 1130–1137.
    OpenUrlAbstract/FREE Full Text
    1. Xie H,
    2. Kim K,
    3. Aglyamov SR,
    4. et al
    . Staging deep venous thrombosis using ultrasound elasticity imaging: animal model. Ultrasound Med Biol 2004; 30: 1385–1396.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wakefield TW,
    2. Strieter RM,
    3. Wilke CA,
    4. et al
    . Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 258–268.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Bonderman D,
    2. Jakowitsch J,
    3. Redwan B,
    4. et al
    . Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2008; 28: 678–684.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Fadel E,
    2. Riou JY,
    3. Mazmanian M,
    4. et al
    . Pulmonary thromboendarterectomy for chronic thromboembolic obstruction of the pulmonary artery in piglets. J Thorac Cardiovasc Surg 1999; 117: 787–793.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Fadel E,
    2. Michel RP,
    3. Eddahibi S,
    4. et al
    . Regression of postobstructive vasculopathy after revascularization of chronically obstructed pulmonary artery. J Thorac Cardiovasc Surg 2004; 127: 1009–1017.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Mitzner W,
    2. Wagner EM
    . Vascular remodeling in the circulations of the lung. J Appl Physiol 2004; 97: 1999–2004.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Wagner EM,
    2. Jenkins J,
    3. Perino MG,
    4. et al
    . Lung and vascular function during chronic severe pulmonary ischemia. J Appl Physiol 2011; 110: 538–544.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Charan NB,
    2. Carvalho P
    . Angiogenesis in bronchial circulatory system after unilateral pulmonary artery obstruction. J Appl Physiol 1997; 82: 284–291.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Fadel E,
    2. Mazmanian GM,
    3. Chapelier A,
    4. et al
    . Lung reperfusion injury after chronic or acute unilateral pulmonary artery occlusion. Am J Respir Crit Care Med 1998; 157: 1294–1300.
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Fadel E,
    2. Mazmanian GM,
    3. Baudet B,
    4. et al
    . Endothelial nitric oxide synthase function in pig lung after chronic pulmonary artery obstruction. Am J Respir Crit Care Med 2000; 162: 1429–1434.
    OpenUrlPubMedWeb of Science
  20. ↵
    1. Shi W,
    2. Hu F,
    3. Kassouf W,
    4. et al
    . Altered reactivity of pulmonary vessels in postobstructive pulmonary vasculopathy. J Appl Physiol 2000; 88: 17–25.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Shi W,
    2. Giaid A,
    3. Hu F,
    4. et al
    . Increased reactivity to endothelin of pulmonary arteries in long-term post-obstructive pulmonary vasculopathy in rats. Pulm Pharmacol Ther 1998; 11: 189–196.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Michel RP,
    2. Hakim TS
    . Increased resistance in postobstructive pulmonary vasculopathy: structure-function relationships. J Appl Physiol 1991; 71: 601–610.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Fadel E,
    2. Wijtenburg E,
    3. Michel R,
    4. et al
    . Regression of the systemic vasculature to the lung after removal of pulmonary artery obstruction. Am J Respir Crit Care Med 2006; 173: 345–349.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Sage E,
    2. Mercier O,
    3. Van den Eyden F,
    4. et al
    . Endothelial cell apoptosis in chronically obstructed and reperfused pulmonary artery. Respir Res 2008; 9: 19.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Mercier O,
    2. Sage E,
    3. de Perrot M,
    4. et al
    . Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. J Thorac Cardiovasc Surg 2009; 137: 1538–1546.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Rendas A,
    2. Lennox S,
    3. Reid L
    . Aorta-pulmonary shunts in growing pigs. Functional and structural assessment of the changes in the pulmonary circulation. J Thorac Cardiovasc Surg 1979; 77: 109–18.
    OpenUrlPubMedWeb of Science
  27. ↵
    1. Rondelet B,
    2. Kerbaul F,
    3. Motte S,
    4. et al
    . Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003; 107: 1329–1335.
    OpenUrlAbstract/FREE Full Text
    1. Reddy VM,
    2. Wong J,
    3. Liddicoat JR,
    4. et al
    . Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol 1996; 271: H562–H570.
    OpenUrlWeb of Science
  28. ↵
    1. Ovadia B,
    2. Reinhartz O,
    3. Fitzgerald R,
    4. et al
    . Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 2003; 284: H480–H490.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Mercier O,
    2. Tivane A,
    3. Raoux F,
    4. et al
    . A reliable piglet model of chronic thrombo-embolic pulmonary hypertension. Am J Respir Crit Care Med 2011; 183: A2415.
    OpenUrl
  30. ↵
    1. Egermayer P,
    2. Peacock AJ
    . Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000; 15: 440–448.
    OpenUrlAbstract
  31. ↵
    1. Lang I
    . Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. Br J Haematol 2010; 149: 478–483.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Bonderman D,
    2. Wilkens H,
    3. Wakounig S,
    4. et al
    . Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33: 325–331.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Bonderman D,
    2. Jakowitsch J,
    3. Adlbrecht C,
    4. et al
    . Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512–516.
    OpenUrlPubMedWeb of Science
  34. ↵
    1. Azarian R,
    2. Wartski M,
    3. Collignon MA,
    4. et al
    . Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med 1997; 38: 980–983.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Galié N,
    2. Manes A,
    3. Branzi A
    . The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227–237.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Moser KM,
    2. Guisan M,
    3. Bartimmo EE,
    4. et al
    . In vivo and post mortem dissolution rates of pulmonary emboli and venous thrombi in the dog. Circulation 1973; 48: 170–178.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Moser KM,
    2. Cantor JP,
    3. Olman M,
    4. et al
    . Chronic pulmonary thromboembolism in dogs treated with tranexamic acid. Circulation 1991; 83: 1371–1379.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Marsh JJ,
    2. Konopka RG,
    3. Lang IM,
    4. et al
    . Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation 1994; 90: 3091–3097.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Kim H,
    2. Yung GL,
    3. Marsh JJ,
    4. et al
    . Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000; 15: 640–648.
    OpenUrlAbstract
  40. ↵
    1. Sato H,
    2. Hall CM,
    3. Griffith GW,
    4. et al
    . Large animal model of chronic pulmonary hypertension. ASAIO J 2008; 54: 396–400.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Lang IM,
    2. Marsh JJ,
    3. Konopka RG,
    4. et al
    . Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 1990–2000.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 41 Issue 5 Table of Contents
European Respiratory Journal: 41 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chronic thromboembolic pulmonary hypertension: animal models
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Chronic thromboembolic pulmonary hypertension: animal models
Olaf Mercier, Elie Fadel
European Respiratory Journal May 2013, 41 (5) 1200-1206; DOI: 10.1183/09031936.00101612

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Chronic thromboembolic pulmonary hypertension: animal models
Olaf Mercier, Elie Fadel
European Respiratory Journal May 2013, 41 (5) 1200-1206; DOI: 10.1183/09031936.00101612
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • ANIMAL MODELS OF PERSISTENT INTRAVASCULAR THROMBOSIS
    • DUAL VASCULAR COMPARTMENT THEORY
    • MODELS REPLICATING PULMONARY ARTERY OBSTRUCTION
    • MODELS REPLICATING LESIONS OF UNOBSTRUCTED PULMONARY ARTERIES
    • ANIMAL MODEL REPLICATING ALL FEATURES OF CTEPH
    • CONCLUSIONS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Childhood asthma: pathogenesis and phenotypes
  • Non-CPAP therapy in obstructive sleep apnoea
  • Sleep apnoea and heart failure
Show more Series

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society